Patent US4530839A successfully refreshed from Google Patents.
US4530839A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Triphasic oral contraceptive
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1983-09-26
•
Granted: 1985-07-23
•
Expires: 2003-09-26
Abstract
Abstract A method of contraception in which an estrogen and a progestogen are administered daily for 21 days, the first seven days at a low contraceptively effective daily dose, the next 7 days at a daily progestogen dose about 1.5-2 times that of the first 7 days, and the next 7 days at a daily progestogen dose of 2-2.5 times that of the first 7 days, provided that the dosage of the estrogen is maintained at a constant level for the entire 21 days.
Inventors
- 👤 Samuel A. Pasquale
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 10:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
126 words
A method of contraception which comprises administering for 21 successive days to a female of childbearing age a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17α-ethinylestradiol and in progestogenic activity to 0.125-0.75 mg of norethindrone for 7 days; for the next 7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17α-ethinylestradiol and in progestogenic activity to 0.50-1.0 mg of norethindrone; and for the next 7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17α-ethinylestradiol and in progestogenic activity of 0.75-2.0 mg of norethindrone; followed by 7 days without estrogen and progestrogen administration, provided that the estrogen daiy dosage is the same for each 7 day period.
Claim 2
Independent Claim
126 words
A method of contraception which comprises administering for 21 successive days to a female of childbearing age a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17α-ethinylestradiol and in progestogenic activity to 0.125-0.75 mg of norethindrone for 7 days; for the next 7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17α-ethinylestradiol and in progestogenic activity to 0.50-1.0 mg of norethindrone; and for the next 7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17α-ethinylestradiol and in progestogenic activity of 0.75-2.0 mg of norethindrone; followed by 7 days without estrogen and progestrogen administration, provided that the estrogen daiy dosage is the same for each 7 day period.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein the estrogen and progestogen are administered orally.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein the estrogen and progestogen are administered in admixture.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein the progestogen is selected from d-norgestrel, norethindrone, progesterone and D-17β-acetoxy-13β-ethyl-17α-ethinyl-gon-4-en-3-one oxime.
Claim 6
Dependent Claim
16 words
The method of claim 1 wherein the estrogen is selected from 17α-ethinylestradiol, estrone, estradiol and estriol.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein the estrogen is 17α-ethinylestradiol and the progestogen is norethindrone.
Claim 8
Dependent Claim
16 words
The method of claim 1 wherein the estrogen is 17α-ethinylestradiol and the progestogen is D-17β-acetoxy-13β-ethyl-17α-ethinyl-gon-4-en-3-one oxime.
Claim 9
Dependent Claim
46 words
The method of claim 1 wherein the estrogen daily dosage is 0.035 mg for each 7 day period and the progestogen daily dosage is 0.5 mg for the first 7 days, 0.75 mg for the second 7 days and 1.0 mg for the third 7 days.
Claim 10
Dependent Claim
93 words
The contraception method of claim 1 which comprises administering for 21 successive days to a female of childbearing age a combination of 17α-ethinylestradiol and norethindrone in a contraceptively effective daily dosage corresponding to 0.035 mg of 17α-ethinylestradiol and 0.50 mg of norethindrone for 7 days; for the next 7 days a daily dosage equal to 0.035 mg of 17α-ethinylestradiol and 0.75 mg of norethindrone; and for the next 7 days a daily dosge equal to 0.035 mg of 17α-ethinylestradiol and 1.0 mg of norethindrone; followed by 7 days without estrogen and progestogen administration.
References Cited (Backward Citations)
US4291028A
Cited
US4378356A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-07-22 | 1989-01-21 | 1989-07-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-07-22 | 1993-01-21 | 1993-07-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-07-22 | 1997-01-21 | 1997-07-23 | $7700.00 | Window Closed / Lapsed |